Lucid Diagnostics LUCD is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Lucid Diagnostics to report an earnings per share (EPS) of $-0.23.
Investors in Lucid Diagnostics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Earnings Track Record
The company's EPS beat by $0.02 in the last quarter, leading to a 2.38% increase in the share price on the following day.
Here's a look at Lucid Diagnostics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.22 | -0.27 | -0.26 | -0.27 |
| EPS Actual | -0.20 | -0.21 | -0.23 | -0.22 |
| Price Change % | 2.0% | -2.0% | -7.000000000000001% | 12.0% |
Market Performance of Lucid Diagnostics's Stock
Shares of Lucid Diagnostics were trading at $1.05 as of November 11. Over the last 52-week period, shares are down 22.56%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Lucid Diagnostics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
